{"id":"NCT01364597","sponsor":"UCB Pharma SA","briefTitle":"Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy","officialTitle":"Open-label, Single-arm, Multicenter, Long-term Study to Evaluate Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Pediatric Subjects With Epilepsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08-01","primaryCompletion":"2022-02-03","completion":"2022-02-03","firstPosted":"2011-06-02","resultsPosted":"2022-08-29","lastUpdate":"2023-12-05"},"enrollment":257,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Brivaracetam (BRV)","otherNames":[]}],"arms":[{"label":"Brivaracetam","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study","timeFrame":"From Baseline to end of study (up to 10 years)","effectByArm":[{"arm":"Age Cohort: ≥1 Month to <2 Years","deltaMin":94.4,"sd":null},{"arm":"Age Cohort: ≥2 to <4 Years","deltaMin":93.3,"sd":null},{"arm":"Age Cohort: ≥4 to <12 Years","deltaMin":93.6,"sd":null},{"arm":"Age Cohort: ≥12 to <17 Years","deltaMin":92.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"28 Days","sex":"ALL","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":26},"locations":{"siteCount":56,"countries":["United States","Belgium","Czechia","France","Germany","Hungary","Ireland","Italy","Mexico","Poland","Spain","United Kingdom"]},"refs":{"pmids":["37597326","26899665"],"seeAlso":["http://www.briviact.com/briviact-PI.pdf?v=1479491757","http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":36},"commonTop":["Nasopharyngitis","Pyrexia","Pharyngitis","Vomiting","Upper respiratory tract infection"]}}